New drug cocktail aims to shrink kidney tumors before surgery
NCT ID NCT07389629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of two immunotherapy drugs (QL1706) and a targeted therapy (lenvatinib) can shrink kidney tumors before surgery. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are currently too complex to operate on safely. About 25 adults with clear cell renal cell carcinoma will receive the drugs for 2 to 4 cycles before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (iparomlimab and tuvonralimab) plus lenvatinib
- What this could lead to
- If successful, this combination could shrink kidney tumors enough to allow safer, kidney-sparing surgery instead of full kidney removal.
- What could go wrong
- This is a small, early-phase trial with only 25 people, so results may not apply to everyone. The drug combination can cause side effects like high blood pressure, fatigue, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, 0755, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?